Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB

Published:2023-02-01 Issue:2 Volume:27 Page:151-153
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Chung C.¹,Shin J. E.¹,Jeon D.²,Kang H.³,Yim J-J.⁴,Jo K-W.¹,Shim T. S.¹

Affiliation:

1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

2. Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea

3. Department of Chest Medicine, Masan National Tuberculosis Hospital, Masan, Republic of Korea

4. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis;Journal of Infection;2023-09

2. Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease;The International Journal of Tuberculosis and Lung Disease;2023-09-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP